ACTUATE THERAPEUTICS, INC. (ACTU): Entry into a Material Definitive Agreement

ACTUATE THERAPEUTICS, INC. (ACTU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering CHICAGO, IL and FORT WORTH, TX, October 27, 2026 — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on devel

Event · Offering · priced
Instrument
common stock and warrants
Gross proceeds
approximately $11.0 million
Shares
30,985,900 shares
Price per share
$0.71 per set of securities
Use of proceeds
working capital and general corporate purposes

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 28, 2026, 9:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ACTU
Neutral
high confidence
Mentioned
$ACTU
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ACTUNeutralMed
01

Why it matters

The $11 M capital raise provides working‑capital but introduces dilution, likely pressuring the share price in the near term.

02

Market read

Primary disclosure of a modest equity raise for a micro‑cap biotech, offering a short‑term trading opportunity.

03

What to watch

Warrant exercise price and optionality may provide additional upside if the stock rallies, partially offsetting dilution.

Relevance 6/10Novelty 7/10Timing: today

Background

Actuate Therapeutics is a clinical‑stage biopharma developing elraglusib for hard‑to‑treat cancers. The company filed an 8‑K to disclose a public offering.

Company-level read

Ticker impact

$ACTUNeutralHigh confidence
Context

Actuate Therapeutics announced pricing of an $11.0 million underwritten public offering of 30.9 million shares and warrants.

Expected impact

likely pressure as the market prices in dilution from the $11 M raise

Evidence & confidence

Primary 8‑K filing, first report of the offering, with clear terms and expected closing today.

Market effects

Adds modest capital to the clinical‑stage biotech sector, may prompt peers to consider similar financing.

Limited to US biotech investors; no broader regional effect.

Low global impact; primarily relevant to ACTU shareholders and biotech capital markets.

Counterpoint

The raise could fund critical R&D milestones, potentially supporting a longer‑term upside despite short‑term dilution.

Key entities

  • Actuate Therapeutics, Inc.

    Clinical‑stage biopharma issuing new shares and warrants.

  • Newbridge Securities Corporation

    Sole book‑running manager for the offering.

Related articles

$ACTUMed

Actuate reports preclinical data on oral elraglusib in melanoma

Actuate Therapeutics (ACTU) reported preclinical data showing its oral drug candidate elraglusib achieved up to 77% tumor growth inhibition in a melanoma model. The company plans to initiate a Phase 1/2 clinical trial in Q1 2027, starting with refractory metastatic melanoma patients. Elraglusib has previously shown promise in a Phase 2 trial for metastatic pancreatic cancer.

$ACTUMedAI 8/10

Actuate Advances Oral Elraglusib Toward 2027 Trial Following Positive Melanoma Data

Actuate Therapeutics (ACTU) reported positive preclinical data for its oral elraglusib tablet, showing tumor growth inhibition and immune-modulating effects in a melanoma mouse model. The company plans to present the findings at the EORTC-NCI-AACR Symposium in November 2026 and initiate a Phase 1/2 clinical trial in Q1 2027. The U.S. Patent Office issued a Notice of Allowance for the oral formulation's patent.

$MARAMed

MARA prices $185M debt offering after $1.1B Bitcoin sale

MARA priced an $185M debt offering at 8.75% interest, maturing in 2032, to finance its $1.5B acquisition of Long Ridge Energy. The deal includes a 485MW power plant and land for potential data centers. MARA recently sold $1.1B in Bitcoin to repay debt. Long Ridge generated $144M in annualized adjusted EBITDA, but interest payments may consume nearly half.

$RIOLow

Rio Tinto commits US$250m to address damage from Bougainville's Panguna mine

Rio Tinto will contribute $250m to a fund addressing environmental and human rights impacts of the Panguna mine, per an agreement with Bougainville Copper Limited, the Autonomous Bougainville Government, and community leaders. The fund aims to support practical responses to identified impacts and social projects. Details will be developed in consultation with communities.